Where to Find CAR-T Cell Therapy for Blood Cancers: A Global Overview (Feb 2023)

CAR-T cell therapy and gene therapy are revolutionary medical breakthroughs that have proved effective in treating previously untreatable hematological malignancies. The success story of CAR-T therapy began with a profound idea in 1989, culminating in the miraculous recovery of 6-year-old Emily Whitehead in 2012, who was considered a lost cause at the time. Emily is still alive today, in 2023.

While there is no one "best" country for CAR-T cell therapy, the availability of the treatment in a patient's home country, as well as their individual needs and circumstances, are crucial factors to consider. Consultation with the healthcare professional treating the patient in their home country is essential to determine the best course of treatment for each patient.

What countries offer FDA Approved Car-T therapy?

Several countries, including the USA, Canada, Germany, France, Spain, the United Kingdom, Italy, ISRAEL, Australia, Singapore, and China, offer FDA-approved CAR-T therapy. However, there are some obstacles to receiving the treatment, such as long waiting times for citizens of the country and high costs, starting at approximately $475,000, due to the need for the patient's blood to travel to the United States under strict freeze conditions for gene engineering before returning to the patient.


CAR-T programs offered as a part of clinical trials

To make CAR-T therapy available to more patients, some medical centers in the USA, China, and Israel offer in-house CAR-T therapy at significantly lower price ranges. In-house CAR-T, or home-grown CAR-T, is created in the medical center's laboratories, preserving the quality of the cells and expediting the procedure.

China and the USA lead in the number of clinical studies involving CAR-T, targeting hematological antigens CD19, BCMA, and more. As of March 10, 2022, China has the highest number of CAR-T cell clinical trials registered on, followed by the US, the UK, and Germany, with 25 countries initiating clinical trials with CAR-T cells. Non-Hodgkin's lymphoma is still the most frequent hematological disease targeted by CAR-T cell therapy, followed by B-ALL, Multiple Myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, while T-cell cancers and Hodgkin's disease are still the minority.

NIH- National Library of Medicine
Single Use Support- biopharma

CAR-T cell therapy in Israel
CAR-T for Leukemia and Lymphoma in Israel
CAR-T for Myeloma in Israel
CAR-T cell therapy for leukemia and non-Hodgkin's lymphoma (NHL) in Europe
CAR-T cell therapy for Multiple Myeloma patients in Europe
CAR-T therapy for international patients
CAR-T therapy in Spain
CAR-T cell therapy in Germany
CAR-T cell therapy in Japan